Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of RJK-RT2831 Injection in Patients With Hematologic Malignancies.

NCT06756451 is registered in ClinicalTrials.gov with Nanjing RegeneCore Biotech Co., Ltd. as lead sponsor.

NCT NCT06756451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06756451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of RJK-RT2831 Injection in Patients With Hematologic Malignancies.
Lead sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 25, 2025
Completion date
July 14, 2028
Enrollment
71 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies